Company intelligence / Profile preview
Amazentis
Lausanne, Switzerlandtimelinenutrition.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Amazentis has shown that Mitopure (Urolithin A) supplementation improved muscle strength by 12% after four months in a clinical study. The company's lead product candidate, AMAZ-02, an oral formulation of urolithin A, is currently advancing in two pivotal Phase 2 clinical trials.
- Therapeutic areas
- OtherRheumatology
- Modalities
- Nutritional supplementsTherapeutic nutrition
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nestlé Health Science
Beyond the preview
Go deeper on Amazentis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amazentis.